baber/WOPTO huggingface dataset:
Patent NZ-521586-A (NZ)
Title: Wine vat or barrel with open rigid frame
Inventor: ANDRIES MARCEL
IPC: B65D/
Filed: 2001-04-10
Abstract: A  wine barrel (1) is described having an  open  rigid frame  (2)  having  sides, a top and a bottom.  Wooden  side panels  are  sealingly arranged on the  sides  of  the  open frame  and  a  top  and  a  bottom plate  are  provided  for completing  the  barrel. The barrel can  be  refurbished  by removing the wooden panels, exposing new wood by removing  a portion  of  the panels which has been exposed to  the  wine and replacing the panels.
Patent NZ-526689-A (NZ)
Title: Particulate matter propulsion apparatus
Inventor: FAIRWEATHER ANDREW PETER
IPC: B42D15/04
Filed: 2001-11-29
Abstract: A particulate matter propulsion apparatus (10) for propelling confetti (94) or similar from a greeting card (12) includes a particulate matter receptacle (14) attached to a supporting means (16), the supporting means being store energy such that when the card is opened the particulate matter is propelled from the card.
Patent NZ-527234-A (NZ)
Title: Teaching method and system
Inventor: LAYNG TERRENCE V
IPC: G09B5/06
Filed: 2002-01-16
Abstract: A method and system provides procedures/routines to teach certain repertoires, such as reading, to learners without a teacher present. The various routines can be provided or implemented via a computer network, such as the Internet, so that multiple learners can access and use the routines. Feedback features take into account that the Internet is a medium where it is difficult to directly monitor the learner's activities during the course of various lessons provided by the routines. The routines may be implemented in a sequence of episodes, with each episode systematically building on the particular skills learned in a prior episode. Some of these routines include establishing routines, adduction routines, potentiating routines, composite routines, sequential composite routines, fluency routines, motivation routines, application routines, and the overall sequencing of these routines.
Patent NZ-530806-A (NZ)
Title: Quinoline derivatives and use thereof as antitumor agents
Inventor: HORWITZ JEROME P
IPC: A61K31/47
Filed: 2002-07-31
Abstract: Quinoline derivatives of formula (I) and pharmaceutically acceptable salts thereof are disclosed, wherein: Y is F, Cl, Br, methyl or methoxy. These compounds are effective antitumor agents and are suitable for medicaments for treating cancer. Pharmaceutical compositions comprising a compound of formula (I) or a salt thereof and intermediates useful for preparing a compound of formula (I) are also disclosed.
Patent NZ-540518-A (NZ)
Title: Novel x-conotoxin peptides (-I)
Inventor: LEWIS RICHARD JAMES
IPC: A61P25/00
Filed: 2003-12-02
Abstract: An isolated, synthetic or recombinant chi-conotoxin peptide comprising the following sequence of amino acids: Xaa1 Xaa2 Gly Val Cys Cys Gly Tyr Lys Leu Cys His Pro Cys SEQ ID NO. 3 where Xaa1 is a N-terminal Xaa1 is a N-terminal pyroglutamate (pGlu) or D-pyroglutamate (DpGlu) residue; and Xaa2 is Asn or a deletion; or such a sequence in which one or more Cys is replaced with its corresponding D-amino acid and/or one or more amino acid residues other than Cys has undergone a side chain modification, or a salt, ester, amide or prodrug thereof. Also described are compositions comprising these peptides and the use of these peptides in the prophylaxis or treatment of incontinence or cardiovascular conditions or diseases, or mood disorders, or for the treatment or control of acute, chronic neuropathic, pain, migraine or inflammation.
Patent NZ-543962-A (NZ)
Title: Improved production of rosuvastatin calcium salt
Inventor: CRABB JEFFREY NORMAN
IPC: C07D/
Filed: 2004-06-03
Abstract: This disclosure concerns a chemical process for the manufacture of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-5 [methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid calcium salt (1) as described in formula 1, which is useful for the production of a pharmaceutical useful in the treatment of, inter alia, hypercholesterolemia, hyperlipoproteinemia and atherosclerosis. More specifically this disclosure relates to a process for the formation of the compound of formula 1, which comprises the steps a) to g): a) reaction of a (1-6C)alkyl ester of (E)-(6-{2-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]vinyl}(4R,6S)-2,2-dimethyl[1,3]dioxan-4yl) acetic acid in a water miscible organic solvent with aqueous acid at an elevated temperature; b) reaction of the resulting solution with an aqueous alkali metal hydroxide and optionally washing the resulting aqueous alkali metal salt solution with a suitable organic, solvent; c) adjustment of the pH of the solution to about pH9-10.5 by addition of aqueous hydrochloric acid; d) removal of the water miscible organic solvent; e) optional filtration of the resulting mixture; f) addition of a water soluble calcium salt to the filtrate so as to form (E)-7-[4-(4- fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5- dihydroxyhept-6-enoic acid calcium salt; and g) isolation of the product of step f).
Patent NZ-544962-A (NZ)
Title: Methods for fabricating cellular cushions
Inventor: FRASER KEVIN GERARD
IPC: B29C45/16
Filed: 2004-07-22
Abstract: A method of fabricating a cellular cushion (10). The method comprises injecting material into a mold in an injection molding process to form a cushion first layer that includes a plurality of hollow cells (14) that extend outward from the base (12) and are each coupled together in flow communication, coupling a second layer to the first layer, and coupling an injection stem in flow communication to the plurality of hollow cells to enable an operating pressure within the cells to be changed.
Patent NZ-548781-A (NZ)
Title: Piperidine derivatives as chemokine modulators (CCR)
Inventor: ALCARAZ LILIAN
IPC: A61K31/445
Filed: 2005-01-31
Abstract: Disclosed are compounds of formula (I) that are modulators of chemokine (for example CCR3) activity (for use in, for example, treating asthma), wherein the variables shown in formula (I) are as defined in the specification.
Patent NZ-553631-A (NZ)
Title: Cover for cooling patients and cooling device comprising a cover of this type
Inventor: BEHRINGER WILHELM
IPC: A61F7/00
Filed: 2005-08-11
Abstract: A cover for cooling at least a part of the body of a patient 1, the cover including at least one cooling element 3 containing a cooling fluid 8 and intended for placement on the body or body part, which cooling element 3 is cooled to below the freezing point of the cooling fluid 8 prior to its application, characterized in that a material having a good thermal conductivity as compared to the cooling fluid 8 is contained in the cooling element 3 to absorb the cooling fluid 8.
Patent NZ-555497-A (NZ)
Title: Fungicidal mixtures comprising prothioconazole and metconazole
Inventor: AMMERMANN EBERHARD
IPC: A01N55/00
Filed: 2003-03-04
Abstract: Disclosed is a fungicidal mixture comprising 2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-[1,2,4]-triazole-3-thione (prothioconazole) of the formula (I) or a salt or adduct thereof, and metconazole of the formula (III) or a salt or adduct thereof.
Patent NZ-555579-A (NZ)
Title: Dispensing closure assembly where rotation of a twist ring causes axial movement of a top to open and closure dispensing outlet
Inventor: LINDSAY BRENDAN JON
Filed: 2005-03-04
Abstract: A dispensing closure assembly where the dispensing pathway is opened by twisting part of the assembly is disclosed. The assembly has three moulded components, a first component (1) that engages with a container, a top (10), and a twist ring (13). The first component (1) has a column (6) with an outlet (7) through which liquid content of the container can egress. The first component has a closure portion above the outlet and the column, in part, defines part of a surrounding annular well. The top is threadedly associated with the first component, fits coaxially about the column, and sits at least partially in the annular well. The top has a dispensing outlet capable of being closed by the closure portion. The twist ring is held captive by, and is rotatable relative to, the first component. The twist ring slidably engages the top to allow axial movement of the twist ring relative to the column, but prevents relative rotation between the top and twist ring. The dispensing outlet is opened and closed by rotation of the twist ring relative to the first component, which causes axial movement of the top relative to the first component reliant on the threaded association.
Patent NZ-561816-A (NZ)
Title: Coffee product with roasted and unroasted portions and chlorogenic acids
Inventor: LELOUP VALERIE MARTINE JEANINE
IPC: A23F5/02
Filed: 2006-04-07
Abstract: Disclosed is a coffee product with roasted and unroasted portions. The coffee product includes: a first portion consisting of unroasted ground and/or unground coffee, in an amount of from 1 to 90% by weight based on the total weight of the coffee product, and; a second portion consisting of ground coffee which has been roasted to a higher degree of roast than the first portion, in an amount of from 99 to 10% by weight based on the total weight of the coffee product. The content of chlorogenic acids is at least 4g per 100g of the coffee product.
Patent NZ-567460-A (NZ)
Title: Cushion and cushion to frame assembly mechanism for patient interface
Inventor: DAVIDSON AARON SAMUEL
IPC: A61M16/06
Filed: 2008-04-16
Abstract: A full-face cushion for a patient interface that delivers breathable gas to a patient, the full-face cushion comprising: a frame connector adapted to attach the cushion to a mask frame; and an interface provided to the frame connector, the interface being constructed of foam and defining a cushion cavity, the foam having at least one portion including a foam contact surface that does not include a skin to interface or contact with surfaces of the patient's face in use, wherein the interface includes different stiffnesses in different regions of the cushion to vary the spring characteristic around the cushion perimeter.
Patent NZ-580185-A (NZ)
Title: Telmisartan composition to treat hypertension
Inventor: THOMAS RUEDIGER
IPC: A61K9/20
Filed: 2008-03-13
Abstract: Disclosed is a pharmaceutical tablet or tablet layer comprising the angiotensin II receptor antagonist telmisartan in amorphous form, a basic agent and sorbitol, wherein the sorbitol has a specific surface area of between 0.75-3.5 m²/g. Also disclosed is the use of the tablet or tablet layer in the manufacture of a medicament for treating chronic stable angina, vasospastic angina, stroke, myocardial infarction, transient ischemic attack, congestive heart failure, cardiovascular disease, diabetes, insulin resistance, impaired glucose tolerance, pre-diabetes, type 2 diabetes mellitus, diabetic nephropathy, metabolic syndrome (syndrome X), obesity, dyslipidemia, hypertriglyceridemia, elevated serum concentrations of C-reactive protein, elevated serum concentrations of lipoprotein(a), elevated serum concentration of homocysteine, elevated serum concentration of low-density lipoprotein (LDL)-cholesterol, elevated serum concentration of lipoprotein-associated phospholipase (A2), reduced serum concentration of high density lipoprotein (HDL)-cholesterol, reduced serum concentration of HDL(2b)-cholesterol, reduced serum concentration of adiponectin, cognitive decline and dementia. Further disclosed is the process for preparing a pharmaceutical tablet or tablet layer. Telmisartan is also known as 4'-[2-n-propyl-4-methyl-6-(1-methylbenzimidazol-2-yl)-benzimidazol-1-ylmethyl]-biphenyl-2-carboxylic acid and has the structure as shown in the drawing.
Patent NZ-580449-A (NZ)
Title: Ingestible medical device with biocompatible polymer coating, device with microarray to interact with disease marker
Inventor: HOLMES ELIZABETH A
IPC: A61B5/15
Filed: 2004-09-10
Abstract: Disclosed is an ingestible medical device to monitor levels of a bodily fluid analyte and release therapeutic agents. The device comprises of: a microarray (4), comprising a bioactive agent capable of interacting with a disease marker biological analyte; at least one reservoir (10) comprising at least one therapeutic agent, and capable of releasing the at least one therapeutic agent from the medical device; at least one microchip; and a biocompatible polymer coating (1) coated on said ingestible medical device. The microchip comprises of: a microarray scanning device (7) capable of obtaining physical parameter data of an interaction between the disease marker biological analyte with the bioactive agent; a biometric recognition device (9) capable of comparing the physical parameter data with an analyte interaction profile; a therapeutic agent releasing device capable of controlling release of the therapeutic agent from the reservoir; and an interface device (8) capable of facilitating communications between the microarray scanning device, the biometric recognition device and the therapeutic agent releasing device. (62) Divided Out of 546432
Patent NZ-586932-A (NZ)
Title: Use of alcohols in fuels for spark ignition engines
Inventor: KUBERKA MELANIE
IPC: C10L1/06
Filed: 2009-02-05
Abstract: Disclosed is the use of at least one C4 alcohol to increase the vapour pressure of a fuel for spark-ignition engines comprising base fuel and ethanol in which use the at least one C4 alcohol is added to a fuel comprising base fuel and ethanol to produce a resultant fuel mixture comprising 15-50 percent by volume of base fuel, 15-65 percent by volume of ethanol and 15 to 50 percent of a C4 alcohol such as isobutanol.
Patent NZ-587349-A (NZ)
Title: Method and apparatus for making aerated food product and product obtainable thereby
Inventor: ABYLOV MELIS
IPC: A23L27/60
Filed: 2010-08-13
Abstract: A method is disclosed for dispensing a foamed product, wherein gas is supplied to the product via a microfiltration device. A product dispensing system is also disclosed, provided with a holder (1) which contains a product to be dispensed, and product discharge means (6) for discharging product coming from the holder (1) wherein the product discharge means (6) are provided with a microfiltration device (15) which is connectable to a fluid supply for supplying gas to the product during dispensing of product.
Patent NZ-593068-A (NZ)
Title: IL-18 antibody
Inventor: GHAYUR TARIQ
IPC: C07H21/04
Filed: 2004-11-12
Abstract: Disclosed is an isolated monoclonal antibody, or antigen binding portion thereof, capable of binding human IL-18, wherein the antibody, or antigen binding portion thereof, comprises: a heavy chain variable region comprising CDR1, CDR2, and CDR3 sequences, and a light chain variable region comprising CDR1, CDR2, and CDR3 sequences, wherein the heavy chain variable region CDR3 sequence comprises an amino acid sequence of residues 99-110 of SEQ ID NO:6, or an amino acid sequence of residues 99-110 of S EQ ID NO:6 containing conservative amino acid substitutions. Further disclosed is an isolated monoclonal antibody, or antigen binding portion thereof, capable of binding human IL-18, that comprises a light chain variable region (VL) comprising SEQ ID NO:7.
Patent NZ-593822-A (NZ)
Title: Feed for preventing and/or treating diseases due to clostridium sp. bacteria in livestock, and anti-clostridium agent
Inventor: NAGASHIMA KYO
IPC: A61K31/05
Filed: 2009-12-14
Abstract: Disclosed is the use of a cashew nut shell liquid, a heat-treated cashew nut shell liquid, anacardic acid, cardanol, or anacardic acid and cardanol in the manufacture of an agent to control a disease caused by a Clostridium bacterium. Also disclosed is the use of a cashew nut shell liquid and/or anacardic acid in the manufacture of an agent to promote weight gain in livestock other than ruminant. Also disclosed is a method of promoting weight gain in livestock other than ruminant, comprising feeding to the livestock other than ruminant a weight gain promoting agent or feed comprising cashew nut shell liquid and/or anacardic acid.
Patent NZ-594172-A (NZ)
Title: Novel polymorphic forms of 6-(1-methyl-1h-pyrazol-4-yl)-2-{ 3-[5-(2-morpholin-4-yl-ethoxy)-pyrimidin-2-yl]-benzyl} -2h-pyridazin-3-one dihydrogenphosphate and processes of manufacturing thereof
Inventor: BECKER AXEL
IPC: A61K31/506
Filed: 2009-11-24
Abstract: 594172 Disclosed herein are crystalline 6-(1-methyl-1H-pyrazol-4-yl)-2-{ 3-[5-(2-morpholin-4-yl-ethyoxy)-pyrimidin-2-yl]-benzyl} -2H-pyradizin-3-one dihydrogenphophate solvates and anhydrates; the use thereof in the treatment of physiological and/or pathophysiological conditions affected by modulation of signal transduction kinases, such as tyrosine kinases or Met-kinase, including cancer; and processes for the preparation thereof comprising recrystallisation from a solvent or solvent mixture and aqueous phosphoric acid solution. Specifically wherein the compound is the crystalline anhydrate, hydrate or dihydrate characterised by XRD peaks disclosed in the specification.
Patent NZ-594866-A (NZ)
Title: Method and user interface for deriving the volume of a bladder from at least one ultrasound image
Inventor: BETTS NICHOLAS
IPC: G01F17/00
Filed: 2011-08-29
Abstract: A handheld touchscreen device (100) and method allowing ultrasound data to be manipulated to calculate the volume of a urinary bladder is disclosed. A first perimeter of the captured ultrasound image of the bladder is defined by the placement of a seed point on the touchscreen (104) by the user within a recognisable cross section of the bladder. The area defining a closed perimeter is then automatically calculated recognising similar echoic intensity within the image. The user is able to more precisely define the perimeter by dragging points of the perimeter to desired location via the touchscreen, the perimeter remains continuous. The volume of the bladder is calculated using the calculations of the first closed perimeter region and preselected data on the physical shape of the bladder. The process is repeated in an adjacent direction to further accurately define the volume of the bladder.
Patent NZ-596607-A (NZ)
Title: Anthelmintic agents and their use
Inventor: CHASSAING CHRISTOPHE PIERRE ALAIN
IPC: A01N43/00
Filed: 2010-06-16
Abstract: 596607 Disclosed herein is a compound of formula (I), wherein the variables are defined in the specification, a pharmaceutical composition, and kit comprising said compound, and a method and the use of said compound for the control of helminth infections, such as nematod, cestode or trematode infection. Embodiments of the compound include the following: 6-(4-{ 2-[4-(4-cyano-3-trifluoromethyl-phenylamino)-cyclohexyloxy]-thioacetyl} -piperazin-1-yl)-nicotinonitrile, 4-(4-{ 2-[4-(5-chloro-pyridin-2-yl)-piperazin-1-yl]-2-thioxoethoxy} -cyclohexylamino)-2-trifluoromethyl-benzonitrile, and 5-(4-{ 2-[4-(4-cyano-3-trifluoromethyl-phenylamino)-cyclohexyloxy]-thioacetyl} -piperazin-1-yl)-pyridine-2-carbonitrile.
Patent NZ-597679-A (NZ)
Title: Novel delta 9-elongase for production of polyunsaturated fatty acid-enriched oils
Inventor: PEREIRA SUZETTE
IPC: C12N9/00
Filed: 2010-07-14
Abstract: 597679 NOVEL DELTA 9-ELONGASE FOR PRODUCTION OF POLYUNSATURATED FATTY ACID-ENRICHED OILS Provided is an isolated nucleic acid or fragment thereof and their variants comprising or complementary to an isolated nucleotide sequence encoding a polypeptide having delta 9-elongase activity. Further provided are corresponding peptide sequences, expression vectors containing the DNA sequences and transgenic plants harbouring the expression vectors. Transgenic plants have an enhanced fatty acid profile.
Patent NZ-617506-A (NZ)
Title: Murgantiol as an indoor stink bug attractant
Inventor: SCHNEIDMILLER RODNEY G
IPC: A01P19/00
Filed: 2012-03-14
Abstract: Provided herein are uses of murgantiol for attracting stink bugs, such as brown marmorated stink bugs, in indoor settings. Stink bug traps comprising murgantiol and methods of using murgantiol in traps indoors are provided. Compositions comprising murgantiol are also described.
Patent NZ-617615-A (NZ)
Title: Improved flat packaging of petri dishes for prolonged preservation and method of producing the same
Inventor: BARNHIZER BRET T
IPC: B65B31/04
Filed: 2012-04-18
Abstract: An improved flat package of petri dishes and method of producing the same for prolonging shelf life and preservation of sterility of the petri dishes for at least 12 months is disclosed. The flat package (10) is comprised of an optically clear, high-barrier, moisture-, gas- and microbial-resistant pouch (14). A plurality of petri dishes (12) located adjacent one another are placed in an interior cavity of the pouch, after which the pouch is vacuum-packed, optionally flushed with an inert gas and then heat sealed. The placement and immobilization of the petri dishes in the pouch allow for prolonged shelf life and preservation of sterility, greatly reduced breakage rates, and enhanced visibility of the petri dishes by a user.
Patent NZ-631363-A (NZ)
Title: Common light chain mouse
Inventor: DAVIS SAMUEL
IPC: C12N15/85
Filed: 2011-02-08
Abstract: Disclosed is a B cell obtained from a mouse, wherein said mouse comprises: (a) an insertion at an endogenous mouse kappa immunoglobulin light chain variable region locus of a rearranged human Vkappa1-39/Jkappa sequence, a human Vkappa3-20/Jkappa sequence, or a combination thereof, wherein the human sequence is operably linked to an endogenous mouse kappa constant gene; and (b) an insertion at an endogenous mouse immunoglobulin heavy chain variable region gene locus with a plurality of human immunoglobulin heavy chain variable gene segments, wherein the human immunoglobulin heavy chain variable gene segments are operably linked to an endogenous mouse immunoglobulin heavy chain constant gene, and the human immunoglobulin heavy chain variable gene segments are capable of rearranging and forming a rearranged human/mouse chimeric immunoglobulin heavy chain gene.
Patent NZ-703321-A (NZ)
Title: Risperidone or paliperidone implant formulation
Inventor: GUTIERRO ADURIZ IBON
IPC: A61P25/18
Filed: 2013-05-31
Abstract: A method for the manufacturing of a composition suitable for forming an in situ solid implant in a body, comprising the steps of: a) providing a biocompatible copolymer based on lactic and glycolic acid having a monomer ratio of lactic to glycolic acid of from 45:55 to 55:45, an initial molecular weight between 50 and 63 kDa and an inherent viscosity in the range of between 0.25-0.31 dl/g ±10%, and irradiating it with gamma or beta radiation in the dose range of 10-30 KGy at a temperature lower than 15°C to adjust its molecular weight to between 30 and 46 kDa and its inherent viscosity to a range of 0.25-0.31 dl/g, and then, b) mixing the resulting polymer with a drug which is risperidone and/or paliperidone or any pharmaceutically acceptable salt thereof in any combination and DMSO as solvent.